Development and characterization of a plant-derived norovirus-like particle vaccine

Shapiro, Janna R.; Andreani, Guadalupe; Dubé, Charlotte; Berubé, Mélanie; Bussière, Diane; Couture, Manon M.-J.; Dargis, Michèle; Hendin, Hilary E.; Landry, Nathalie; Lavoie, Pierre-Olivier; Pillet, Stéphane; Ward, Brian J.; D'Aoust, Marc-André; Trépanier, Sonia

doi:10.1016/j.vaccine.2023.08.036

Cited by 1 publication

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown that various types of biologics could be produced by plants, including antibodies, vaccines, therapeutic proteins, and cytokines [ 19 , 20 , 21 ]. Plant expression platforms are safe and cost-effective.…”

Section: Introductionmentioning

confidence: 99%

Exploring the Potentiality of a Plant Platform for Monoclonal Antibody Production in Veterinary Medicine

Morel,

Favrot,

Mirande

et al. 2024

Vaccines

View full text Add to dashboard Cite

Canine atopic dermatitis (CAD) is an allergic, inflammatory, and pruritic skin disease associated with the production of IgE antibodies against environmental allergens and mainly house dust mite allergens. This complex dermatological pathology involves Interleukin 31 (IL-31) as a central itch mediator. One of the most effective CAD treatments is a caninized monoclonal antibody (mAb) called Lokivetmab. It is produced in CHO cells and targets specifically canine IL-31 (cIL-31) and blocks its cellular messaging. This treatment has undoubtedly contributed to a breakthrough in dermatitis-related pruritus. However, its production in mammalian cells requires time-consuming procedures, high production costs, and investment. Plants are considered an emerging protein production platform for recombinant biopharmaceuticals due to their cost-effectiveness and rapidity for production. Here, we use transient expression in Nicotiana benthamiana plants to produce recombinant canine Interleukin 31 (cIL-31) and an anti-IL-31 monoclonal antibody (M1). First, we describe the production and characterization of M1 and then its activity on an IL-31-induced pruritic model in dogs compared to its commercial homolog. Dogs treated with the plant-made M1 mAb have shown similar improvements to Lokivetmab-treated ones after different challenges using canine IL-31. Furthermore, M1 injections were not associated with any side effects. These results demonstrate the safety and efficacy of this plant-made Lokivetmab biosimilar to control dogs’ pruritus in a well-established model. Finally, this study shows that the plant-production platform can be utilized to produce rapidly functional mAbs and bring hope to the immunotherapy field of veterinary medicine.

show abstract

Section: Introductionmentioning

confidence: 99%